Galectin Therapeutics reported $-7.42M in EBITDA for its fiscal quarter ending in December of 2021.





Ebitda Change Date
AbbVie USD 6.91B 3.22B Jun/2026
Bristol-Myers Squibb USD 3.48B 1.6B Sep/2026
Galectin Therapeutics USD -7.42M 819K Dec/2021
Gilead Sciences USD -9.31B 12.82B Jun/2026
Immunic USD -22.78M 753K Jun/2024
Incyte USD 778.57M 410.6M Jun/2026
Merck USD 1.42B 2.97B Jun/2026